FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220854061> ?p ?o ?g. }

• W4220854061 abstract "Abstract Background Integrin alpha 2 (ITGA2) has been recently reported to be an oncogene and to play crucial roles in tumor cell proliferation, invasion, metastasis, and angiogenesis. Our previous study showed that ITGA2 was overexpressed in pancreatic cancer and promoted its progression. However, the mechanism of ITGA2 overexpression and other mechanisms for promoting the progression of pancreatic cancer are still unclear. Methods The GEPIA database was used to confirm the expression of ITGA2 in pancreatic cancer. To verify the influence of ITGA2 and TGF-β on the morphological changes of pancreatic cancer and tumor cell progression, we conduct CCK8 test, plate cloning, flow cytometry experiments and animal experiments. Then we conduct Western blot, RT-qPCR to explore the relationship between ITGA2 and TGF-β, and then find the key molecules which can regulate them by immunoprecipitation, Western blot, RT-qPCR, CHIP, nuclear and cytoplasmic separation test. Results The results of the present study show that the abnormal activation of KRAS induced the overexpression of ITGA2 in pancreatic cancer. Moreover, ITGA2 expression significantly suppressed the activation of the TGF-β pathway. ITGA2 silencing enhanced the anti-pancreatic cancer proliferation and tumor growth effects of TGF-β. Mechanistically, ITGA2 expression suppressed the activation of the TGF-β pathway by inhibiting the SMAD2 expression transcriptionally. In addition, it interacted with and inhibited the nuclear translocation of TFCP2, which induced the SMAD2 expression as a transcription factor. Furthermore, TFCP2 also induced ITGA2 expression as a transcription factor, and the TFCP2 feedback regulated the ITGA2-TFCP2-SMAD2 pathway. Conclusions Taken together, these results indicated that ITGA2 expression could inhibit the activation of the TGF-β signaling pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Therefore, ITGA2, by effectively enhancing the anti-cancer effects of TGF- β, might be a potential clinical therapeutic target for pancreatic cancer." @default.
• W4220854061 created "2022-04-03" @default.
• W4220854061 creator A5009540913 @default.
• W4220854061 creator A5047606978 @default.
• W4220854061 creator A5064246278 @default.
• W4220854061 creator A5065705224 @default.
• W4220854061 creator A5068473579 @default.
• W4220854061 creator A5070066511 @default.
• W4220854061 date "2022-02-22" @default.
• W4220854061 modified "2023-10-14" @default.
• W4220854061 title "Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis" @default.
• W4220854061 cites W1949469490 @default.
• W4220854061 cites W1976534761 @default.
• W4220854061 cites W2017483542 @default.
• W4220854061 cites W2031505107 @default.
• W4220854061 cites W2035653659 @default.
• W4220854061 cites W2088085588 @default.
• W4220854061 cites W2097358179 @default.
• W4220854061 cites W2105101128 @default.
• W4220854061 cites W2129063289 @default.
• W4220854061 cites W2144578935 @default.
• W4220854061 cites W2154568166 @default.
• W4220854061 cites W2347012456 @default.
• W4220854061 cites W2434623374 @default.
• W4220854061 cites W2484335322 @default.
• W4220854061 cites W2548379965 @default.
• W4220854061 cites W2765989969 @default.
• W4220854061 cites W2789515459 @default.
• W4220854061 cites W2801349845 @default.
• W4220854061 cites W2891907489 @default.
• W4220854061 cites W2903264947 @default.
• W4220854061 cites W2925187261 @default.
• W4220854061 cites W2937823726 @default.
• W4220854061 cites W2939500465 @default.
• W4220854061 cites W2963546382 @default.
• W4220854061 cites W2972959386 @default.
• W4220854061 cites W2992546630 @default.
• W4220854061 cites W3009903374 @default.
• W4220854061 cites W3012255501 @default.
• W4220854061 cites W3012701113 @default.
• W4220854061 cites W3021319325 @default.
• W4220854061 cites W3023998523 @default.
• W4220854061 cites W3026029040 @default.
• W4220854061 cites W3092011917 @default.
• W4220854061 cites W3110572638 @default.
• W4220854061 cites W3129231381 @default.
• W4220854061 cites W3158556495 @default.
• W4220854061 cites W3177546055 @default.
• W4220854061 cites W3197279608 @default.
• W4220854061 cites W4210976084 @default.
• W4220854061 doi "https://doi.org/10.1186/s13046-022-02286-5" @default.
• W4220854061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35193647" @default.
• W4220854061 hasPublicationYear "2022" @default.
• W4220854061 type Work @default.
• W4220854061 citedByCount "3" @default.
• W4220854061 countsByYear W42208540612022 @default.
• W4220854061 countsByYear W42208540612023 @default.
• W4220854061 crossrefType "journal-article" @default.
• W4220854061 hasAuthorship W4220854061A5009540913 @default.
• W4220854061 hasAuthorship W4220854061A5047606978 @default.
• W4220854061 hasAuthorship W4220854061A5064246278 @default.
• W4220854061 hasAuthorship W4220854061A5065705224 @default.
• W4220854061 hasAuthorship W4220854061A5068473579 @default.
• W4220854061 hasAuthorship W4220854061A5070066511 @default.
• W4220854061 hasBestOaLocation W42208540611 @default.
• W4220854061 hasConcept C104317684 @default.
• W4220854061 hasConcept C118131993 @default.
• W4220854061 hasConcept C119056186 @default.
• W4220854061 hasConcept C121608353 @default.
• W4220854061 hasConcept C126322002 @default.
• W4220854061 hasConcept C185592680 @default.
• W4220854061 hasConcept C2776415932 @default.
• W4220854061 hasConcept C2780210213 @default.
• W4220854061 hasConcept C2781018059 @default.
• W4220854061 hasConcept C2781080636 @default.
• W4220854061 hasConcept C29537977 @default.
• W4220854061 hasConcept C502942594 @default.
• W4220854061 hasConcept C55493867 @default.
• W4220854061 hasConcept C71924100 @default.
• W4220854061 hasConcept C86339819 @default.
• W4220854061 hasConcept C86803240 @default.
• W4220854061 hasConcept C95444343 @default.
• W4220854061 hasConceptScore W4220854061C104317684 @default.
• W4220854061 hasConceptScore W4220854061C118131993 @default.
• W4220854061 hasConceptScore W4220854061C119056186 @default.
• W4220854061 hasConceptScore W4220854061C121608353 @default.
• W4220854061 hasConceptScore W4220854061C126322002 @default.
• W4220854061 hasConceptScore W4220854061C185592680 @default.
• W4220854061 hasConceptScore W4220854061C2776415932 @default.
• W4220854061 hasConceptScore W4220854061C2780210213 @default.
• W4220854061 hasConceptScore W4220854061C2781018059 @default.
• W4220854061 hasConceptScore W4220854061C2781080636 @default.
• W4220854061 hasConceptScore W4220854061C29537977 @default.
• W4220854061 hasConceptScore W4220854061C502942594 @default.
• W4220854061 hasConceptScore W4220854061C55493867 @default.
• W4220854061 hasConceptScore W4220854061C71924100 @default.
• W4220854061 hasConceptScore W4220854061C86339819 @default.
• W4220854061 hasConceptScore W4220854061C86803240 @default.
• W4220854061 hasConceptScore W4220854061C95444343 @default.
• W4220854061 hasFunder F4320321001 @default.

• next